MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-06-2026
Zomedica Corp. Net Debt 2011-2026 | ZOM
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Zomedica Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.83 M | -5.21 M | -10.2 M | -25.7 M | -194 M | 466 K | -511 K | -1.94 M | -3.45 M | -82.1 K | -143 K | -207 K | -79.7 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 466 K | -194 M | -19 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Drug manufacturers industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Evoke Pharma
EVOK
|
-13.4 M | - | - | $ 36.6 M |  USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-934 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
-6.59 M | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
-8.8 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-22.5 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-11.1 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-676 K | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
-11.2 M | - | - | $ 142 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-6.5 M | $ 5.58 | 0.9 % | $ 82.9 M | USA |
 |
Cronos Group
CRON
|
-790 M | $ 2.74 | 2.43 % | $ 1.05 B |  Canada |
 |
Harrow Health
HROW
|
178 M | $ 32.74 | 6.09 % | $ 1.2 B | USA |
 |
Athenex
ATNX
|
-28.3 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-49.7 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
4.58 B | - | - | $ 11.5 B | USA |
 |
HEXO Corp.
HEXO
|
-150 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Organogenesis Holdings
ORGO
|
-75.9 M | $ 2.66 | 4.31 % | $ 337 M | USA |
 |
Pacira BioSciences
PCRX
|
317 M | $ 23.52 | 2.26 % | $ 1.09 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
2.43 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
7.37 B | - | - | $ 28.9 M |  Irlanda |
 |
Bausch Health Companies
BHC
|
21.1 B | $ 5.45 | -0.73 % | $ 1.99 B | Canada |
 |
Canopy Growth Corporation
CGC
|
193 M | $ 1.07 | 4.22 % | $ 115 M | Canada |
 |
Tilray
TLRY
|
14.4 M | $ 5.46 | 0.83 % | $ 3.37 B | Canada |
 |
Solid Biosciences
SLDB
|
-38.7 M | $ 6.5 | 0.46 % | $ 569 M | USA |
 |
Aurora Cannabis
ACB
|
-95 M | $ 3.57 | 2.88 % | $ 196 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-5.29 M | $ 1.07 | - | $ 1.33 M | USA |
 |
Jupiter Wellness
JUPW
|
-21.7 K | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
529 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
-102 M | $ 1.14 | 6.07 % | $ 109 M | Canada |
 |
cbdMD
YCBD
|
-521 K | $ 0.77 | 3.13 % | $ 3.1 M | USA |
 |
Evolus
EOLS
|
94.8 M | $ 6.46 | -2.05 % | $ 416 M | USA |
 |
Sundial Growers
SNDL
|
-28.4 M | $ 1.47 | 1.74 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
338 M | $ 8.37 | 2.39 % | $ 429 M | USA |
 |
Veru
VERU
|
-12.7 M | $ 2.19 | 0.92 % | $ 32.1 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-101 M | - | - | $ 193 M | Canada |
 |
Assertio Holdings
ASRT
|
29.1 M | $ 23.41 | -0.15 % | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
-6.41 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-111 M | - | - | $ 1.42 B | USA |
 |
PetIQ
PETQ
|
329 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
-2.5 M | $ 7.23 | 0.84 % | $ 285 M | USA |
 |
Recro Pharma
REPH
|
-6.65 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-72.2 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-19.1 M | $ 0.72 | 8.52 % | $ 36 M | USA |
 |
PLx Pharma
PLXP
|
-21.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
11.3 B | $ 16.5 | -0.57 % | $ 19.2 B | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-50.3 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-730 K | $ 0.79 | -3.26 % | $ 28.4 M | USA |
 |
Tricida
TCDA
|
-7.08 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-162 K | $ 0.76 | 1.04 % | $ 3.26 M |  China |
 |
TherapeuticsMD
TXMD
|
-1.39 M | $ 2.06 | -0.96 % | $ 23.8 M | USA |